Efficacy and safety of cyclosporine in acute myocardial infarction: A systematic review and meta-analysis

Firdaus A. Rahman, Siti S. Abdullah, Wan Zanariah W.A. Manan, Loh Teng Hern Tan, Chin Fen Neoh, Long Chiau Ming, Kok Gan Chan, Learn Han Lee, Bey Hing Goh, Shahrzad Salmasi, David Bin Chia Wu, Tahir M. Khan

Research output: Journal PublicationReview articlepeer-review

21 Citations (Scopus)

Abstract

There are various studies that have addressed the use of Cyclosporine among patients with acute myocardial infarction (AMI). However, to date there is hardly any concise and systematically structured evidence that debate on the efficacy and safety of Cyclosporine in AMI patients. The aim of this review is to systematically summarize the overall evidence from published trials, and to conduct a meta-analysis in order to determine the efficacy and safety of Cyclosporine vs. placebo or control among patients with AMI. All randomized control trial (RCT) published in English language from January 2000 to August 2017 were included for the systematic review and meta-analysis. A total of six RCTs met the inclusion and were hence included in the systematic review and meta-analysis. Based on the performed meta-analysis, no significant difference was found between Cyclosporine and placebo in terms of left ventricular ejection fraction (LVEF) improvement (mean difference 1.88; 95% CI -0.99 to 4.74; P = 0.2), mortality rate (OR 1.01; 95% Cl 0.60 to 1.67, P = 0.98) and recurrent MI occurrence (OR 0.65; 95% Cl 0.29 to 1.45, P = 0.29), with no evidence of heterogeneity, when given to patients with AMI. Cyclosporine also did not significantly lessen the rate of rehospitalisation in AMI patients when compared to placebo (OR 0.91; 95% Cl 0.58 to 1.42, P = 0.68), with moderate heterogeneity (I2 = 46%). There was also no significant improvement in heart failure events between Cyclosporine and placebo in AMI patients (OR 0.63; 95% Cl 0.31 to 1.29, P = 0.21; I2 = 80%). No serious adverse events were reported in Cyclosporine group across all studies suggesting that Cyclosporine is well tolerated when given to patients with AMI. The use of Cyclosporine in this group of patients, however, did not result in better clinical outcomes vs. placebo at improving LVEF, mortality rate, recurrent MI, rehospitalisation and heart failure event.

Original languageEnglish
Article number238
JournalFrontiers in Pharmacology
Volume9
Issue numberJUN
DOIs
Publication statusPublished - 19 Jun 2018
Externally publishedYes

Keywords

  • Acute myocardial infraction
  • Cyclosporine
  • Efficacy
  • Meta-analysis
  • Safety

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Efficacy and safety of cyclosporine in acute myocardial infarction: A systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this